Pasithea Therapeutics Announces Completion Of GMP Manufacturing For PAS-004
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics has announced the completion of Good Manufacturing Practice (GMP) manufacturing for its product PAS-004.
June 29, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics, listed as KTTA, has completed GMP manufacturing for PAS-004, which could potentially lead to increased revenues.
The completion of GMP manufacturing for PAS-004 by Pasithea Therapeutics indicates that the product is ready for market, which could potentially lead to increased revenues for the company. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100